How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?

de Ramon Ortiz, Carmen; Wang, Sisi; Stathis, Anastasios; Bertoni, Francesco; Zenz, Thorsten; Novak, Urban; Simonetta, Federico (2024). How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma? Hematological oncology, 42(1), e3237. Wiley 10.1002/hon.3237

Text Hematological_Oncology_-_2023_-_Ramon_Ortiz_-_How_to_integrate_CD19_specific_chimeric_antigen_receptor_T_cells_with_other.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (795kB)

About one third of patients with diffuse large B-cell lymphoma (DLBCL) have a relapsing/refractory (R/R) disease after first line chemo-immunotherapy, with particularly poor outcomes observed in patients with primary refractory disease and early relapse. CD19 specific chimeric antigen receptor (CAR) T cell therapy is a game changer that results in durable and complete response rates in almost half of the patients with R/R DLBCL. Other emerging CD19-targeting therapies include monoclonal antibodies, bispecific antibodies and targeting antibody-drug conjugates, which also show encouraging results. However, the timing and sequencing of different anti-CD19-targeting agents and how they might interfere with subsequent CAR T cell treatment is still unclear. In this review, we summarize the results of the pivotal clinical trials as well as evidence from real-world series of the use of different CD19-targeting approved agents. We discuss the effect of various therapies on CD19 expression and its implications for treatment sequencing.

Interest & Impact

Downloads

1 since deposited on 08 Nov 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item